Supplementary table

Sensitivity analyses using 3 and 6 month cut-offs for start of testosterone therapy among current users and 15-, 30- and 60-day grace periods

	Cases n (%)	Controls n (%)	Rate ratio (95% CI)	
			Crude	Adjusted[a]
15-day grace period	19215	909530		
No recent T use	19124 (99.53)	907444 (99.77)	1	1
Current T use	64 (0.33)	1164 (0.13)	1.84 (1.41 - 2.41)	1.24 (0.93 - 1.66)
T started ≤ 3 months	26 (0.14)	477 (0.05)	1.95 (1.30 - 2.94)	1.39 (0.91 - 2.13)
T started > 3 months	38 (0.20)	687 (0.08)	1.77 (1.25 - 2.50)	1.15 (0.80 - 1.67)
T started ≤ 6 months	36 (0.19)	630 (0.07)	1.97 (1.39 - 2.81)	1.37 (0.95 - 2.00)
T started > 6 months	28 (0.15)	534 (0.06)	1.69 (1.13 - 2.53)	1.10 (0.73 - 1.68)
T started ≤ 9 months	**42 (0.22)**	**710 (0.08)**	**2.02 (1.46 - 2.81)**	**1.44 (1.02 - 2.04)**
T started > 9 months	22 (0.11)	454 (0.05)	1.56 (0.99 - 2.45)	0.97 (0.60 - 1.55)
30-day grace period	19215	909530		
No recent T use	19124 (99.53)	907433 (99.77)	1	1
Current T use	69 (0.36)	1251 (0.14)	1.84 (1.42 - 2.38)	1.25 (0.94 - 1.66)
T started ≤ 3 months	23 (0.12)	395 (0.04)	2.07 (1.34 - 3.21)	1.49 (0.95 - 2.35)
T started > 3 months	46 (0.24)	856 (0.09)	1.74 (1.26 - 2.38)	1.15 (0.82 - 1.62)
T started ≤ 6 months[b]	**36 (0.19)**	**529 (0.06)**	**2.26 (1.58 - 3.23)**	**1.63 (1.12 - 2.37)**
T started > 6 months[b]	33 (0.17)	722 (0.08)	1.53 (1.06 - 2.21)	1.00 (0.68 - 1.47)
T started ≤ 9 months	**40 (0.21)**	**635 (0.07)**	**2.08 (1.48 - 2.92)**	**1.52 (1.06 - 2.17)**
T started > 9 months	29 (0.15)	616 (0.07)	1.58 (1.07 - 2.34)	1.00 (0.66 - 1.51)
60-day grace period	19215	909530		
No recent T use	19124 (99.53)	907416 (99.77)	1	1
Current T use	72 (0.37)	1378 (0.15)	1.70 (1.31 - 2.19)	1.15 (0.87 - 1.52)
T started ≤ 3 months	15 (0.08)	259 (0.03)	2.04 (1.18 - 3.53)	1.50 (0.86 - 2.62)
T started > 3 months	57 (0.30)	1119 (0.12)	1.62 (1.22 - 2.15)	1.08 (0.79 - 1.47)
T started ≤ 6 months	**27 (0.14)**	**407 (0.04)**	**2.26 (1.50 - 3.41)**	**1.66 (1.08 - 2.54)**

T started > 6 months	45 (0.23)	971 (0.11)	1.47 (1.07 - 2.02)	0.96 (0.68 - 1.35)
T started ≤ 9 months	**36 (0.19)**	**508 (0.06)**	**2.34 (1.63 - 3.36)**	**1.76 (1.21 - 2.56)**
T started > 9 months	36 (0.19)	870 (0.10)	1.33 (0.94 - 1.89)	0.83 (0.57 - 1.21)

CI: confidence interval; T: testosterone; VTE: venous thromboembolism.

Current testosterone treatment defined as a prescription whose duration included the index date

[a] Adjusted for age, history of primary or secondary hypogonadism, surgical procedures, medical illness, trauma, and active cancer factors in the 90 days before the index day, and for history of cancer 91 or more days prior to the index date. (matching factors), smoking, BMI, alcohol, socioeconomic status, any history of polycythemia, chronic pulmonary disease, diabetes, congestive heart failure, myocardial infarction, peripheral vascular disease and stroke, sexual dysfunction, tiredness and a covariate comprising osteoporosis, infertility, loss of appetite and hot flushes, and use of corticosteroids, megestrol, nonsteroidal anti-inflammatory drugs and antiplatelets.